Compare MAMA & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | AGMB |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 652.5M |
| IPO Year | 2011 | 2024 |
| Metric | MAMA | AGMB |
|---|---|---|
| Price | $13.46 | $11.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $19.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 732.7K | 171.8K |
| Earning Date | 04-14-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | $17.86 |
| P/E Ratio | $135.00 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $9.90 | $8.75 |
| 52 Week High | $21.00 | $17.82 |
| Indicator | MAMA | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 38.63 |
| Support Level | $13.06 | $9.54 |
| Resistance Level | $15.25 | $12.83 |
| Average True Range (ATR) | 0.87 | 1.35 |
| MACD | -0.18 | -0.30 |
| Stochastic Oscillator | 14.05 | 6.62 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.